Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience by Khurum Khan et al.
Khan et al. BMC Cancer  (2015) 15:15 
DOI 10.1186/s12885-015-1014-6RESEARCH ARTICLE Open AccessPrognostic factors and treatment outcomes in
patients with Small Bowel Adenocarcinoma (SBA):
The Royal Marsden Hospital (RMH) experience
Khurum Khan†, Clare Peckitt†, Francesco Sclafani†, David Watkins†, Sheela Rao†, Naureen Starling†, Vikram Jain†,
Sachin Trivedi†, Susannah Stanway†, David Cunningham† and Ian Chau*†Abstract
Background: SBA is a rare tumour which carries a poor prognosis. Very few data on prognostic factors and
treatment outcomes are available. We conducted a retrospective analysis of patients treated for SBA at our
institution.
Methods: Clinico-pathological characteristics, treatments and outcomes of all the SBA patients treated consecutively
from 1996 to 2011 were retrospectively collected. The prognostic value of baseline factors was assessed using the Cox
regression model. The Kaplan-Meier method was used to estimate the survival outcomes.
Results: Eighty-four patients with SBA were treated during the study period. Of these, 48 presented with early stage
SBA, while 36 had unresectable disease. All early stage SBA patients (58.3% males; median age, 59 years) underwent
resection (R0 in 44/48) and 27 (56%) received adjuvant chemotherapy. Median relapse-free survival and overall survival
(OS) were 31.1 months (95% CI: 8.0-54.3) and 42.9 (95% CI: 0–94.9), respectively. In univariate analyses, poor histological
differentiation (p = 0.025) and lymphovascular invasion (p = 0.003) were prognostic for OS. In the group of patients with
relapsed, unresectable or metastatic disease (n = 59), systemic chemotherapy was administered in 46 cases (78%). The
response rate to first line chemotherapy was 50%. Median progression-free survival and OS were 8.8 (95% CI: 5.5-12.3)
and 12.8 months (95% CI: 8.4-17.2), respectively. In univariate analyses, low albumin (p = 0.041) and high platelet count
(p = 0.007) were prognostic for OS.
Conclusion: Prospective clinical trials are needed to inform the management of SBA patients. Prognostic factors
evaluated in our series may be useful for patient stratification and treatment selection in future studies.Background
Although small bowel accounts for 75% of the total
length of the entire intestine, tumours arising from the
small intestine are relatively rare [1], accounting for ≤5%
of all gastrointestinal tract cancers. Small bowel ade-
nocarcinoma (SBA) is the second commonest tumour
involving the small bowel after carcinoid tumours [1].
The estimated new cases per year in US and Europe are
5300 and 3500 respectively with estimated mortality of
1,210 and 1100 deaths per year [2,3].
The outcome from SBA remains poor across all stages,
with a median overall survival (OS) of about 19 months* Correspondence: ian.chau@rmh.nhs.uk
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unless otherwise stated.and an overall 5-year OS of around 30% [4]. More im-
portantly, given the rarity of this disease, there is a lack
of data from randomised, prospective studies and the
management of these tumours is generally based on data
from small retrospective series or is inferred from the
available evidence on other tumour types.
Indeed, due to its anatomical proximity to large bowel
and the presence of some clinico-pathological com-
monalities with colorectal cancer (CRC), SBA is often
assimilated to the adenocarcinoma arising from the large
bowel and largely treated according to the management
recommendations for CRC. However, the natural history
of the two diseases is significantly different. It is recog-
nised that SBA and CRC differ for their clinical features
and tumour-related symptoms at presentation. Moreover,
it is thought that the impact of surgery and chemotherapyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is significantly lower than in CRC, perhaps suggesting that
SBAs may have a more aggressive phenotype than CRCs
and are less sensitive to the treatments used for CRC.
Finally, as a result of the low prevalence of this disease and
the scarcity of clinical data, there are no validated prognos-
tic factors or tumour biomarkers for SBA which may help
clinicians stratify patients according to their individual risk
profile, predict the clinical benefit of specific treatment
strategies and accurately monitor the course of disease.
In this scenario, prospective clinical trials which pro-
vide high level evidence to inform the management of
SBA both in the early stage and metastatic setting are
urgently needed. However, until the results of these
studies are available, clinical data from retrospective
series may offer useful insights into the natural history
and treatment outcomes of SBA.
In this article, we report the clinical characteristics and
outcomes of patients treated consecutively for SBA at
The Royal Marsden Hospital over a fifteen year period.
Methods
This retrospective study included all patients with SBA
consecutively treated at the Royal Marsden National
Health Service (NHS) Foundation Trust, United Kingdom,
from January 1996 to December 2011. Only patients who
had confirmed histological diagnosis of SBA were in-
cluded. Patient medical records were reviewed and the fol-
lowing clinico-pathologic parameters were collected for all
patients included in the study: age, gender, site of origin of
the primary tumour, histological subtype, tumour grade,
clinical stage at diagnosis, presenting features including
weight loss (defined as unintentional loss of body weight
of at least 10%, during the last six months), full blood
count, biochemical profiles (including alkaline phospha-
tase [ALP], bilirubin, lactate dehydrogenase [LDH] and
albumin) and CEA. For patients undergoing resection of
the primary tumour, type of surgery (R0 vs. R1 vs. R2),
lymphovascular invasion (LVI), perineural invasion (PNI),
number of lymph nodes harvested (LNH), and number of
lymph nodes involved (LNI) were also collected. Details
on systemic treatments were collected for the whole study
population. Patients were divided into two groups; those
with early stage SBA (ES-SBA) included patients who pre-
sented with potentially resectable disease and late stage
SBA (LS-SBA). LS-SBA included patients who presented
or relapsed with un-resectable disease at a later stage.
The study was approved by the local Research Ethics
Committee.
Clinical presentation and response evaluation
Clinical symptoms at initial presentation were collected
as originally recorded and prospectively reported in the
electronic medical records (EMR). Baseline tumourmeasurements were performed within 2–4 weeks prior
to treatment start in all the patients included in this
study. In patients with ES-SBA, as per policy of our in-
stitution, surveillance guidelines included annual tumour
assessments by computed tomography (CT) scan for
first three years, followed by clinical monitoring for sub-
sequent two years. In patients with LS-SBA, tumour
measurements were repeated every 12 weeks or earlier if
progression of disease (PD) was suspected. All the scans
were reported using, Response Evaluation Criteria In
Solid Tumours (RECIST) version 1.0. Tumour responses
were confirmed prospectively by a radiologist. Whole
body PET scans were performed only when clinically in-
dicated. Survival data were obtained from the hospital
EMR, and when necessary, by contacting the general
practitioner or referring institution.
Statistical methods
The study endpoints were relapse free survival (RFS) and
overall survival (OS), in ES-SBA; while in LS-SBA, pro-
gression free survival (PFS) and OS were the study end-
points. RFS was defined as the time between the date of
surgery to date of relapse or death in patients who under-
went R0 resection; PFS was defined as the time from date
of diagnosis to date of progression or death and, OS as the
date of diagnosis to date of death. Patients event-free were
censored at date of last follow-up. In LS-SBA, response
rate (RR) to chemotherapy was also established. Complete
response (CR) was defined as complete disappearance of
the tumor. Partial response (PR) was defined as more than
30% decrease in the maximum diameter of measurable
disease, in the absence of progression in non-target lesions
or new disease. Progressive disease (PD) was defined as
more than a 20% increase in the maximum diameter of
measurable disease, or as evidence of new disease or pro-
gression in non-target lesions. Stable disease (SD) was de-
fined as the disease that did not fit the category of PR or
PD [7]. Treatment was stopped in patients with radio-
logical evidence of disease progression according to the
above-mentioned criteria. Association to baseline prog-
nostic factors were sought by performing Cox regression
univariate analysis (UVA).
Categorisation of numeric laboratory variables was
undertaken based on considerations of the standard refer-
ence values (normal range versus low/elevated) or ac-
cording to the median values. Survival estimates and
95% confidence intervals [CI] were determined using the
Kaplan-Meier method, and estimates between groups
were compared using the log-rank test for baseline prog-
nostic factors. Cox regression analysis was used to calcu-
late respective hazard ratios and 95% CIs. Multivariate
Cox regression was used to test independence of signifi-
cant (p < 0.1) factors in univariate analysis. P-values <0.05
were considered significant.
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Patient and tumour characteristics
A total of 84 patients with SBA were treated at the
RMH, during the study time period. Forty eight and 59
patients had ES-SBA and LS-SBA respectively; 23 pa-
tients from ES-SBA relapsed later and became un-
resectable and thus were also included in LS-SBA group.
The median age at presentation in ES-SBA and LS-SBA
were 59 (mean = 57, range 28–78) and 61 (mean = 59,
range 28–87) respectively. Most patients had duodenal
tumours in both groups; 62.5% in ES-SBA and 67.8% in
LS-SBA. In ES-SBA, 44 (91.6%) patients underwent R0
resection of their disease, while 27 (55.1%) patients
received adjuvant chemotherapy. Of the patients with
LS-SBA, 54 (91.5%) had metastatic and 5(8.5%) had
localised but un-resectable disease. Forty six (78%) pa-
tients received first line chemotherapy. A summary of all
the baseline features has been provided in Table 1.
Presenting features
Abdominal pain was the commonest presenting symp-
tom in both ES and LS-SBA, accounting for 34.3% and
55.3% of the initial presenting symptoms of the two
groups respectively. Other common presenting symp-
toms in the two groups included nausea, vomiting, small
bowel obstruction and weight loss. A small proportion
of patients presented with haematemesis or melaena
(Table 2). In ES-SBA, 44.7% of the patients presented
with abnormal CEA, low haemoglobin (63.2%), low
albumin (42.1%), high LDH (48%), high ALP (36.8%) and
abnormal ALT (21.6%). In LS-SBA, the abnormal labora-
tory parameters included, low haemoglobin (78.4%), high
CEA (75.6%), low albumin (47.1%), high LDH (43.9%),
high ALP (43.1%) and high ALT (20%).
Survival outcomes
The median RFS in patients with ES-SBA after a median
follow up of 76.4 (95% CI = 39.3 – 113.5) months, defined
by the interval between the date of surgery to relapse or
death in patients with R0 resection was 29.6 months (95%
CI = 3.3-55.9). The OS defined by date of diagnosis to date
of death was 42.9 months (95% CI = 0-94.9). The 5-year
RFS and OS were 34.1% (95% CI = 19.0-49.2) and 47.7%
(95% CI = 31.2-64.2) respectively.
In the LS-SBA group the median PFS was found to be
8.8 months (95% CI = 5.5-12.3) and OS was 12.8 months
(CI = 8.4-17.2), after a median duration of follow up of
63.7 months (95% CI = 16.5-110.9) (Figures 1 and 2).
Prognosticators of survival
Poor histological differentiation, abnormal CEA at pre-
sentation and LVI were prognostic of OS and for RFS in
ES-SBA, using univariate cox regression analysis. These
results are summarised in Tables 3 and 4. In multivariateanalysis including any factors with p < 0.1 only LVI
remained significant for OS at p < 0.05 and primary
tumour (p = 0.02) and grade (0.006) remained significant
for RFS, however this is based on a model including only
35 subjects due to missing data.
Abnormal albumin at diagnosis (p = 0.041), platelet
count (p = 0.007) and CEA levels (p = 0.025) were prog-
nostic of OS in patients with LS-SBA, who received
chemotherapy. Doublet (18/41) vs. triplet (23/41) che-
motherapy regimens had no prognostic impact on OS
(p = 0.185) (Figure 3). 5/41 patients received single agent
chemotherapy. These results are summarised in Tables 5
and 6. In multivariate analysis including any factors with
p < 0.1 only platelets remained significant for OS at
p < 0.05 and only albumin remained significant for PFS,
however this is based on a model including only 33 sub-
jects due to missing data.
First-line chemotherapy efficacy in LS-SBA
Of the forty six patients, who received first-line chemo-
therapy (median 6 cycles, range 1–12), 40 were evaluable
for response assessment by RECIST criteria. ORR was
found to be 50% [1(2.5%) CR, 19 (47.5%) PR]; whilst 8
(20%) and 12 (30%) were found to have SD and PD as
their best response. Patents had a median follow up time
of 63.7 months (95% CI = 16.5-110.9). Patients who re-
ceived chemotherapy had an overall 1-year survival of
60.9% (95% CI = 45.8-76.0). When compared to patients
who didn’t receive chemotherapy, the survival was sig-
nificantly better (P = 0.042), as only 27.3% were alive at
1-year time point. Of the 23 patients that received triplet
regimens, EOX (Epirubicin, oxaliplatin and capecitabine;
n = 13), ECX (Epirubicin, cisplatin and capecitabine; n = 4),
ECF (Epirubicin, cisplatin and 5-FU; n = 3), E-Carbo-F
(Epirubicin, carboplatin and 5-FU; n = 2) were commonly
prescribed regimens in the order of descending frequency;
one patients received Mitomycin C in combination with
carboplatin and 5-FU. Whilst of the 18 patients who were
offered doublet chemotherapy combinations, the com-
monly prescribed regimens in the order of descending
frequency included CAPOX (capecitabine and oxaliplatin;
n = 6), FOLFOX (5-FU and oxaliplatin; n = 4), FOLFIRI
(5-FU and irinotecan; n = 3), and capecitabine with
Mitomycin C (n = 3); the remaining two patients received
gemcitabine with capecitabine, and gemcitabine in com-
bination with bevacizumab respectively. When compared,
no statistically significant difference was found in the OS
of patients treated with triplet (23/41) vs. doublet (18/41)
regimens in univariate analysis (p = 0.185) (Figure 3).
Second-line chemotherapy efficacy in LS-SBA
Patients who received second line chemotherapy were
found to have a RR of 63.2%; however, no significant im-
provement in PFS or OS were observed when patients
Table 1 Demographics/tumour characteristics
ES-SBA LS-SBA
N (%) = 48 N (%) = 59
Gender
Male 28 (58.3) 31 (52.5)
Female 20 (41.7) 28 (47.5)
Age (mean & range) 57 (28–78) 59 (28 – 87)
Median 59 61
Site of Primary tumour
Duodenum 30 (62.5) 40 (67.8)
Jejunum 10 (20.8) 11 (18.6)
Ileum 7 (14.6) 8 (13.6)
Small bowel unknown 1 (2.1) 0 (0)
Grade (differentiation)




≤12 21 (43.8) N/A
>12 16 (33.3)
Missing 11 (22.9)
Nodes involved (in those harvested) N/A
Negative (stage I/II) 30 (62.5)
Positive (Stage III) 12 (25.0)
Missing 6 (12.5)
LVI








R0 44 (91.6) N/A
R1 4 (8.4)
Adjuvant Chemo





Locally Advanced N/A 5 (8.5)
Metastatic 54 (91.5)
Table 1 Demographics/tumour characteristics (Continued)
First Line Chemo
No N/A 13 (22.0)
Yes 46 (78.0)
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to those who didn’t receive second-line chemotherapy
(Tables 5 and 6).
Discussion
SBA is a relatively rare but highly aggressive disease.
There is paucity of literature and expertise in manage-
ment of this disease due to lack of prospective clinical
studies evaluating the management strategies in SBA.
Although the disease remains rare, there has been a
trend towards better and early diagnosis of SBA in
recent times due to the advancements in diagnostic in-
vestigations including video-capsule endoscopy and/or
double balloon enteroscopy. Our series is one of the
largest to consider clinical and pathological characteris-
tics of SBA. In our series, patients were divided into two
clinically relevant groups; we sought to gain clinically
meaningful information about both groups within the
limitations of retrospective nature of this study.
In ES-SBA, the role of adjuvant chemotherapy remains
unclear due to lack of any phase III clinical trials eva-
luating the role of adjuvant chemotherapy. Our data and
that of others, however, show that even after curative
resection, more than half of the patients with ES-SBA
succumb to metastatic disease [4,8]. The role of adjuvant
chemotherapy has often been debated as some physi-
cians considered the disease similar to CRC, where the
role of adjuvant chemotherapy is better defined while
others treated it as upper GI cancer where although the
role of peri-operative chemotherapy is well established, the
role of adjuvant chemotherapy remains debatable. How-
ever, more recently some studies [9,10] have shown the
molecular similarities between SBA and CRC. ThereforeTable 2 Symptoms present at diagnosis
ES-SBA LS-SBA
% %
Abdominal Pain 34.3 55.3
Nausea 27.8 41.3
Vomiting 27.8 38.3
Small Bowel Obstruction 22.2 19.1




Acute abdomen perforation 0 0
Figure 1 Overall survival and relapse free survival in early stage-SBA.
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lar similarities with CRC, logically there might be a role for
considering adjuvant chemotherapy in ES-SBA. Our lim-
ited knowledge from previously published retrospective
work however shows no convincing evidence in favour of
adjuvant chemotherapy [11-13]. The only positive expe-
rience from a single-centre study demonstrated improve-
ment in disease free survival (HR 0.27; 95% CI 0.07–0.98,
p = 0.05) but not in OS (HR 0.47; 95% CI 0.13–1.62,
p = 0.23) in a multivariate analysis [14]. The present study
also failed to demonstrate survival advantage in favour of
adjuvant chemotherapy. This however, we think may beFigure 2 Overall survival and progression free survival in late stage-Sdue to selection bias and retrospective data collection; pa-
tients with high risk disease tend to be offered chemo-
therapy which may impair the comparison between the
patients who received or didn’t receive chemotherapy. A
prospective international phase-III study (the BALLAD
study), which is currently in setup, promoted by the Inter-
national Rare Cancer Initiative, will be able to address the
role of adjuvant chemotherapy in SBA.
Previous studies have determined pT4 tumour stage,
poor histological differentiation, positive resection mar-
gins, LVI and low number of LNH as the poor prog-
nostic factors in ES-SBA [11,15,16]. There is conflictingBA.








Gender Male 16/24 23.1 (3.7 – 42.5) 1.58 (0.74 – 3.36) 0.236
Female 12/20 45.0 (23.2 – 66.8) -
Primary tumour 13/27 54.3 (34.3 – 74.3) - (p = 0.019)
Duodenum 8/9 11.1 (0 – 31.7) 1.91 (0.78 – 4.65) 0.154
Jejunum 6/7 0 3.54 (1.28 – 9.7) 0.014
Ileum 1/1 0 0.016
Small bowel unknown 15.9 (1.69 – 150)
Grade (differentiation) Low/Moderate 13/27 47.2 (26.4 – 68.0) -
Poor 14/16 15.0 (0 – 33.6) 3.16 (1.43 – 6.97) 0.004
Nodes harvested <12 15/20 50.3 (30.3 – 70.3) -
≥12 4/14 74.1 (48.8 – 99.4) 0.41 (0.14 – 1.24) 0.113
Nodes involved Negative (Stage I/II) 15/30 40.8 (21.2 – 60.4) -
8/9 1.90 (0.80 - 4.51) 0.144
Positive (Stage III) 33.3 (2.5 – 64.1)
LVI No 7/18 55.1 (27.9 – 82.3) -
Yes 15/19 25.3 (5.3 – 45.3) 3.18 (1.28 – 7.89) 0.013
PNI No 14/27 38.7 (18.3 – 59.1) -
Yes 8/10 40.0 (9.6 – 70.4) 1.27 (0.53 – 3.06) 0.589
Adjuvant Chemo No 11/20 42.3 (18.8 – 65.8) -
Yes 17/24 28.1 (8.9 – 47.3) 1.26 (0.58 – 2.74) 0.555
Small Bowel Obstruction None 14/25 42.8 (22.2 – 63.4) -
Present 6/8 0 1.95 (0.74 – 5.15) 0.180
Weight loss None 16/27 36.1 (16.3 – 55.9) -
Present 4/6 33.3 (0 – 70.9) 1.45 (0.48 – 4.36) 0.505
CEA at baseline Normal 8/19 53.8 (29.5 – 78.1) -
Abnormal 13/15 26.7 (4.4 – 49.0) 2.25 (0.93 – 5.46) 0.074
Haemoglobin Normal 9/14 36.4 (9.0 – 63.8) -
Abnormal 14/20 35.0 (14.0 – 56.0) 1.13 (0.49 – 2.61) 0.781
Albumin Normal 12/19 38.5 (15.6 – 61.4) -
Abnormal 11/15 33.3 (9.4 – 57.2) 1.09 (0.48 – 2.48) 0.838
LDH Normal 8/12 33.3 (3.7 – 62.9) -
Abnormal 7/11 36.4 (8.0 – 64.8) 0.88 (0.32 – 2.45) 0.808
Alk.Ph Normal 13/21 39.8 (18.0 – 61.6) -
Abnormal 10/13 30.8 (5.7 – 55.9) 1.08 (0.47 – 2.47) 0.858
ALT Normal 16/26 40.0 (20.6 – 59.4) -
Abnormal 6/7 28.6 (0 – 62.1) 1.23 (0.48 – 3.18) 0.671
Platelets Normal 24/40 38.0 (21.7 – 54.3) -
Abnormal 1/1 0 4.15 (0.52 – 33.2) 0.180
Where the normal values are:
CEA: ≤ 3.
Platelets: 150 – 400 × 109/l.
Hemoglobin: Male: 13.0 – 17.0 mg/l .
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Gender Male 15/28 41.0 (19.8 – 62.2) 1.81 (0.79 – 4.15) 0.160
Female 9/20 55.5 (33.2 – 76.8) -
Primary tumour Duodenum 12/30 60.3 (40.9 – 79.7) - (0.046)
Jejunum 7/10 30.0 (1.6 – 58.4) 1.61 (0.63 – 4.11) 0.316
Ileum 4/7 33.3 (0 – 70.9) 1.97 (0.63 – 6.22) 0.246
Small bowel unknown 1/1 0 28.4 (2.48 – 326.5) 0.007
Grade Low/(differentiation) 10/27 56.9 (36.7 – 77.1) -
Moderate Poor 14/20 34.8 (12.7 – 56.9) 2.58 (1.13 – 5.89) 0.025
Nodes harvested <12 12/21 42.9 (21.7 – 64.1) -
≥12 6/16 69.6 (44.3 – 94.9) 0.75 (0.28 – 2.01) 0.572
Nodes involved Negative (Stage I/II) 13/30 49.7 (30.1 – 69.3) -
Positive (Stage III) 9/12 41.7 (13.9 – 69.5) 1.64 (0.70 – 3.84) 0.259
LVI No 3/18 78.6 (57.0 – 100) -
Yes 17/22 30.0 (10.4 – 49.6) 6.73 (1.95 – 23.2) 0.003
PNI No 13/29 51.4 (31.4 – 71.4) -
Yes 7/11 45.5 (16.1 – 74.9) 1.42 (0.56 – 3.55) 0.460
Adjuvant Chemo No 10/21 42.0 (18.5 – 65.5) -
Yes 14/27 52.1 (32.3 – 71.9) 0.93 (0.41 – 2.11) 0.867
Small Bowel Obstruction None 13/28 46.9 (26.9 – 66.9) -
Present 5/8 29.2 (0 – 63.1) 1.75 (0.62 – 4.97) 0.294
Weight loss None 14/29 45.0 (25.6 – 64.4) -
Present 4/7 33.3 (0 – 70.9) 1.92 (0.63 – 5.84) 0.252
CEA at baseline Normal 7/21 65.0 (44.0 – 86.0) 2.29 (0.90 – 5.82) 0.082
Abnormal 12/17 37.5 (13.8 – 61.2) -
Hemoglobin Normal 7/14 44.5 (16.5 – 72.5) -
Abnormal 15/24 43.5 (23.3 – 63.7) 1.27 (0.52 – 3.31) 0.604
Albumin Normal 12/22 46.7 (24.9 – 68.5) -
Abnormal 10/16 40.0 (15.3 – 64.7) 1.14 (0.49 – 2.65) 0.756
LDH Normal 7/13 48.0 (18.6 – 77.4) -
Abnormal 7/12 50.0 (21.8 – 78.2) 0.87 (0.30 – 2.52) 0.874
Alk.Ph Normal 14/24 43.1 (22.5 – 63.7) -
Abnormal 8/14 46.2 (19.2 – 73.2) 0.75 (0.31 – 1.79) 0.512
ALT Normal 16/29 46.0 (27.4 – 64.6) -
Abnormal 5/8 42.9 (6.2 – 79.6) 1.05 (0.38 – 2.89) 0.921
Platelets Normal 21/43 50.9 (35.0 – 66.8) -
Abnormal 1/2 0 6.68 (0.77 – 57.6) 0.084
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ciated with poor outcome [9,14]. In the present series,
poor histological differentiation, LVI and abnormal CEA
at presentation were prognostic of OS. Tumour site and
LNH were not found to be prognostic of survival. RFS
and OS in our series were similar or slightly better than
those published previously. 5-year RFS and OS were
43.1% and 47.7% respectively in our series. These resultsmay reflect the high volume of GI surgeries and asso-
ciated expertise in our centre, along with higher median
follow up time compared to some previously published
studies. Furthermore, patients who were deemed resec-
table, most of the times underwent R0 resection of their
disease; although due to small number of patients with
R1 resection in our series, the comparison between the
outcomes of R0 (n = 44) and R1 (n = 4) resection didn’t
Figure 3 Overall survival by doublet vs. triplet chemotherapy
in late stage-SBA.





Primary tumour Duodenum 28/34
Jejunum 5/7
Ileum 4/5
Disease status Locally Advanced 2/2
Metastatic 35/44
Chemo 1ST line Doublet 15/18
Triplet 19/23
Chemo 2nd line No 18/17
Yes 19/19
Small Bowel Obstruction None 22/28
Present 6/8
Weight loss None 15/23
Present 13/13














Khan et al. BMC Cancer  (2015) 15:15 Page 8 of 11reach statistical significance. Of note, of the 27 patients
who received adjuvant chemotherapy in our series, 3
had R1 resection; one patient with R1 resection did not
receive adjuvant chemotherapy.
The role of chemotherapy in LS-SBA is relatively better
defined. Several retrospective series [11,17-26] have shown
the efficacy of chemotherapy in LS-SBA, with RR of
7-42%, PFS of 3.2-8.6 months and OS of 9.0-17.8 months.
Notably, combination chemotherapy has been reported to
be associated with better outcomes compared to single
agent chemotherapy; although no head to head compari-
son has been made and the data should be interpreted
with caution. Only a handful of phase II prospective stu-
dies have examined the role of palliative chemotherapy in
LS-SBA; whilst slightly better RR were observed in those








20.2 (2.8 – 37.6) 1.69 (0.88 – 3.24) 0.115
39.4 (17.3 – 61.5) -
23.8 (7.5 – 40.1) - (0.179)
28.6 (0 – 62.1) 0.50 (0.19 – 1.33) 0.164
60.0 (17.1 – 100) 0.45 (0.15 – 1.32) 0.146
50.0 (0 – 100) -
28.4 (13.9 – 42.9) 1.35 (0.32 – 574) 0.683
25.0 (4.2 – 45.8) -
34.1 (12.5 – 55.7) 1.05 (0.53 – 2.09) 0.884
27.9 (8.1 – 47.7) -
31.6 (10.6 – 52.6) 1.17 (0.61 – 2.24) 0.633
19.8 (2.7 – 36.9) -
42.9 (6.2 – 79.6) 0.69 (0.27 – 1.75) 0.437
28.6 (6.1 – 51.1) -
23.1 (0 – 46.0) 1.29 (0.61 – 2.73) 0.499
66.7 (35.9 – 97.5) -
12.8 (0 – 26.3) 3.18 (1.23 – 8.19) 0.017
48.0 (15.9 – 80.1) -
20.5 (4.6 – 36.4) 1.88 (0.83 – 4.24) 0.130
44.4 (22.1 – 66.7) -
6.7 (0 – 19.4) 2.29 (1.12 – 4.66) 0.023
34.4 (10.9 – 57.9) -
20.0 (0 – 40.2) 1.48 (0.70 – 3.15) 0.310
34.8 (13.0 – 56.6) -
18.8 (0 – 38.0) 1.32 (0.66 – 2.62) 0.437
31.2 (13.6 – 48.8) -
16.7 (0 – 45.7) 1.95 (0.82 – 4.61) 0.131
43.6 (21.8 – 65.4) -
11.8 (0 – 27.1) 2.32 (1.14 – 4.73) 0.020








Gender Male 16/24 57.1 (35.7 – 78.5) 1.06 (0.53 – 2.11) 0.869
Female 17/22 64.6 (43.4 – 85.8) -
Primary tumour Duodenum 26/34 56.5 (38.5 – 74.5) - (0.130)
Jejunum 5/7 71.4 (37.9 – 100) 0.55 (0.21 – 1.45) 0.224
Ileum 2/5 75.0 (32.5 – 100) 0.27 (0.06 – 1.17) 0.080
Disease status Locally Advanced 9/13 67.7 (41.4 – 94.0) -
Metastatic 22/27 51.6 (31.8 – 71.4) 1.99 (0.90 - 4.42) 0.089
Chemo 1ST line Doublet 11/18 52.6 (28.5 – 76.7) -
Triplet 19/23 64.8 (43.6 – 86.0) 1.67 (0.78 – 3.55) 0.185
Chemo 2nd line No 18/17 27.9 (8.1 – 47.7) -
Yes 19/19 31.6 (10.6 – 52.6) 1.17 (0.61 – 2.24) 0.633
Small Bowel Obstruction None 21/28 55.3 (35.3 – 75.3) -
Present 4/8 51.4 (11.4 – 91.4) 0.55 (0.19 – 1.61) 0.274
Weight loss None 13/23 49.4 (25.1 – 73.7) -
Present 12/13 61.5 (35.0 – 88.0) 1.11 (0.50 – 2.45) 0.803
CEA at baseline Normal 5/9 66.7 (35.9 - 97.5) -
Abnormal 23/27 52.2 (32.4 – 72.0) 3.15 (1.15 – 8.60) 0.025
Hemoglobin Normal 8/10 90.0 (71.4 – 100) -
Abnormal 22/29 46.2 (26.6 – 65.8) 1.51 (0.67 – 3.43) 0.323
Albumin Normal 15/22 80.4 (63.2 – 97.6) -
Abnormal 15/17 32.1 (9.2 – 55.0) 2.15 (1.03 – 4.46) 0.041
LDH Normal 13/18 63.6 (39.9 – 87.3) -
Abnormal 13/16 53.3 (28.0 – 78.6) 1.31 (0.59 – 2.87) 0.507
Alk.Ph Normal 16/23 70.5 (50.3 – 90.7) -
Abnormal 14/16 43.8 (19.5 – 68.1) 1.45 (0.70 – 2.99) 0.320
ALT Normal 23/30 63.4 (45.2 – 81.6) -
Abnormal 6/8 31.3 (0 – 66.2) 1.96 (0.77 – 4.96) 0.156
Platelets Normal 15/24 73.4 (55.0 – 91.8) -
Abnormal 16/17 38.0 (14.1 – 61.9) 2.85 (1.34 – 6.08) 0.007
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spective studies [27-29]. In the present series, our data are
comparable to previously published data. It is noteworthy
that in our series, most of the patients had metastatic dis-
ease (54/59) at presentation; additionally 23 patients pre-
sented with relapsed disease. This may overall represent
difficult disease biology to treat. Patients with SBA have
been traditionally treated with variety of chemotherapy
regimens due to lack of randomised phase III data and
incertitude about the molecular behaviour of SBA until
recently. We therefore compared the impact of triplet
(23/41) vs. doublet (18/41) chemotherapy regimens and
found no statistically significant difference in the PFS or
OS between these treatments in univariate analysis. More-
over, the RR to doublet (41.2%) and to the triplet (52.2%)
regimens was found to be statistically insignificant(p = 0.491). The heterogeneity of the treatment regimens
in this setting reflects the historical debate about the na-
ture of SBA. To our knowledge, this is the first series
reporting the comparison between the outcomes of the
patients treated with triplet or doublet chemotherapy
regimens. Our results either reflect the absence of true
difference in the outcomes when treated with triplet or
doublet therapy or may indeed simply reflect the low
power of the study to demonstrate a statistically signifi-
cant difference. Patients who received systemic chemo-
therapy in the present study had a significantly higher
1 year-survival of 60.9%, compared to 27.3% for those who
didn’t receive systemic treatment (p = 0.042). These results
however should be interpreted with caution due to retro-
spective nature of the study and inherent bias towards
selection of patients who were offered chemotherapy.
Khan et al. BMC Cancer  (2015) 15:15 Page 10 of 11The prognostic factors including poor histological dif-
ferentiation and abnormal CEA at presentation have
been established as poor prognostic factors from the
previously published literature in LS-SBA. Our series
was in agreement with these established findings; addi-
tionally we found that low albumin and abnormal plate-
let count were prognostic of worse outcome for both
PFS and OS. Abnormal platelet count has been con-
sidered as an important prognostic factor in CRC based
on the data from UK COIN study [30], whilst we have
previously reported an association of abnormal albumin
with poor outcomes in upper GI cancers [31].
In the current study although we didn’t aim to analyse
the histopathological and molecular biomarkers, more
recently, it has been suggested that SBA has striking mo-
lecular similarities with CRC [9]; this perhaps suggests
that much better outcomes should be achieved in SBA if
more prospective randomised studies were designed to
inform treatment strategies. Acknowledging the impact
of extrapolation of data from other cancers in SBA and
retrospective nature of most of the published literature,
we believe that there is still significant scope of improve-
ment in outcome of patients with SBA. We acknowledge
the limitations of the current study including, single
centre experience, small sample size and inherent selec-
tion bias that is associated with retrospective studies.
We therefore feel that prospective clinical studies in-
corporating molecular targeted therapies coupled with
development of robust biomarkers will help achieving
better outcomes in this disease.
Conclusion
SBA is a rare but highly aggressive disease. Due to pau-
city of available data, and difficulties in setting up large
randomised clinical trials, retrospective data could be
valuable in determining the outcome from the disease
and indeed providing more useful information to the
treating physicians. Our dataset is one of the largest
examinations of this disease in both early stage and
advanced setting. Although patients treated in our series
didn’t appear to have driven any meaningful benefit
from adjuvant chemotherapy; patients with advanced
SBA appear to derive benefit from systemic chemothe-
rapy. Prospective clinical trials are however required to
define optimal chemotherapy regimens. Clinical prog-
nostic factors evaluated in our series may be useful for
stratification and eligibility considerations in future clin-
ical trials.
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